| Identification | Back Directory | [Name]
RORγt inhibitor 1 | [CAS]
2079892-79-6 | [Synonyms]
RORγt inhibitor 1
RORγt Inverse agonist 8
(S)-N-(8-((4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl)methyl)-7-methylimidazo[1,2-a]pyridin-6-yl)-2-methylpyrimidine-5-carboxamide | [Molecular Formula]
C26H33N7O2 | [MDL Number]
MFCD34469367 | [MOL File]
2079892-79-6.mol | [Molecular Weight]
475.59 |
| Hazard Information | Back Directory | [Description]
GKN92796, also known as RORγt inhibitor 1, is a RORγt inhibitor. This product has no formal name at the moment. | [Uses]
RORγt Inverse agonist 8 is a potent, selective, orally bioavailable RORγt inverse agonist, with an IC50 of 19 nM for human RORγt-LBD[1]. | [in vivo]
RORγt Inverse agonist 8 (15 mg/kg, 45 mg/kg ; i.g.; twice daily; for 7 days) ameliorates antigen-induced arthritis (AiA) responses in Lewis rats[1].
| Animal Model: | Female Lewis rats (190–220 g)[1] | | Dosage: | 15 mg/kg, 45 mg/kg | | Administration: | Oral gavage; twice daily; for 7 days | | Result: | Ameliorates antigen-induced arthritis (AiA) responses in Lewis rats. |
| [References]
[1] Guendisch U, et al. Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo. PLoS One. 2017 Nov 20;12(11):e0188391. DOI:10.1371/journal.pone.0188391 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|